Extensions

Patent Term Adjustments (PTA) and Patent Term Extensions (PTE)

The provided patent text and search results do not explicitly state any Patent Term Adjustments (PTA) or Patent Term Extensions (PTE) for US Patent 10313077.

Patent Term Adjustment (PTA) is an extension to the patent term granted to compensate for certain delays caused by the USPTO during the prosecution of a utility or plant patent application. This was established by the American Inventors Protection Act of 1999 for applications filed on or after May 29, 2000. Delays typically fall into categories such as the USPTO failing to: issue a first office action within 14 months, respond to an applicant's reply within 4 months, issue a patent within 4 months of the issue fee payment, or issue a patent within 36 months from the filing date. However, any accrued PTA can be reduced if delays are caused by the applicant.

Patent Term Extension (PTE), under 35 U.S.C. § 156, is typically related to delays in the regulatory review process for products, most commonly pharmaceutical products, by agencies like the FDA. This extension is limited to a single patent covering the product and can be up to five years, but not beyond 14 years after FDA approval.

Since there's no mention of a pharmaceutical product or FDA approval in the patent text or search results, it's highly unlikely that US10313077 would be eligible for PTE. To definitively confirm PTA, access to the USPTO's Patent Center for this specific patent would be required, as PTA is calculated and recorded by the USPTO during prosecution.

Continuation, Divisional, and Related Family Members

US Patent 10313077 is identified as a continuation of International Patent Application No. PCT/KR2016/006976, filed on June 29, 2016. The international application claims priority to:

• Korean Patent Application No. 10-2015-0092525, filed on June 29, 2015.
• Korean Patent Application No. 10-2015-0117434, filed on August 20, 2015.

The patent also lists other versions/family members:

• US20180123757A1 (publication of the US application).

Additionally, the Google Patents page for US10313077 indicates priority claims to:

• US16/396,635 (which resulted in US10651992B2), prioritized on April 27, 2019.
• US16/835,305 (which resulted in US11128421B2), prioritized on March 31, 2020.
• US17/408,296 (which resulted in US11700084B2), prioritized on August 20, 2021.
• US18/206,081 (which resulted in US12149354B2), prioritized on June 6, 2023.
• US18/913,806 (which resulted in US20250119240A1), prioritized on October 11, 2024.

A continuation application is a second application for the same invention disclosed in a prior, co-pending parent application, without introducing new subject matter, and aims to pursue additional claims or different claim scope. A divisional application also shares the same disclosure and priority date as the parent but is filed when the USPTO determines that the parent application contains claims directed to multiple inventions, requiring the applicant to restrict the claims in the parent. There is no explicit mention of divisional applications in the provided text.

Projected Expiration Date

The statutory patent term for U.S. patents filed on or after June 8, 1995, is 20 years from the earliest filing date of the application or any application for which a benefit is claimed under 35 U.S.C. §§ 120, 121, or 365(c).

US Patent 10313077 claims priority to Korean Patent Application No. 10-2015-0092525, filed on June 29, 2015.

Therefore, the anticipated expiration date for US Patent 10313077, absent any patent term adjustments or extensions, would be June 29, 2035.

The Google Patents page for US10313077 lists an "Anticipated expiration" date of 2036-06-29. This suggests that there might be a patent term adjustment (PTA) of approximately one year, or a different earliest priority date being considered for the patent term calculation. Without access to the official USPTO patent prosecution history for US10313077, the exact reason for this discrepancy cannot be definitively determined.